Proposed delivery method is via endoscopic ultrasound, gastroenterologists are getting quite adept at being able to biopsy pancreatic lesions, I expect this will require similar skills. Applying Sirtex SirSpheres for liver tumours requires an interventional radiologist skilled in the method, plus a nuclear medicine work up to assess the vasculature and exclude significant shunts. I don't think that Oncosil delivery will be more complicated, most big centres will be just as capable.
Congratulations to those who have held on today. I personally sold in January after delayed CE mark, but happy to buy back today. More confident CE will also be delivered now if the FDA were satisfied, which should deliver some revenue. It will still be some time before we get any meaningful clinical trial data, but positive step forward, this will be an interesting stock to watch
OSL Price at posting:
16.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)